spontaneous intracranial hemorrhage
Conditions
Interventions
early antiplatelet treatment group:the use of antiplatelet treatment in 3 days postoperatively
control group:none
Sponsors
Beijing Tiantan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18-70 years; 2.nontraumatic spontaneous intracerebral hemorrhage; 3.postoperative patients with high risk of MACCPE: (1)previous history of cerebral infarction or TIA. (2)previous history of coronary heart disease or myocardial infarction. (3) use ASCVD Risk Estimator Plus (http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/) to assess the risk of ischemic events for patients with no previous history of cerebral infarction, TIA, or coronary heart diseases or myocardial infarction,10 years risk>10% is defined as a high risk of cardiovascular ischemic events (4)The Caprini Risk Scale is used to assess the risk of venous thrombosis in the lower extremities.Score > 2 is defined as a high risk of venous thrombosis. 4.patients who received neurosurgical procedures to remove the hematoma, including craniotomy, endoscopic hematoma removal and hematoma aspiration. 5.patients who signed informed consent. 6.no history of allergy to salicylic acid preparation. 7.patients who complete the preintervention assessment and meet the fellow criteria: (1)postoperative head CT showed no new infarction or hemorrhage; (2)postoperative venous ultrasound of the lower extremity did not reveal deep vein thrombosis; (3)postoperative electrocardiogram and myocardial enzyme examination did not show acute myocardial ischemia or myocardial infarction.
Exclusion criteria
Exclusion criteria: 1.There are structural cerebrovascular lesions (such as intracranial aneurysms, cerebrovascular malformations, etc.) or tumors in the area of bleeding or the bleeding is suspected to be related to these lesions. 2.ischemic stroke with hemorrhagic conversion. 3.secondary bleeding due to venous embolism. 4.the malignant tumor is expected to have a survival of no more than 3 months. 5.take antithrombotic agents((Vitamin K antagonists (warfarin) new anticoagulants(Dabigatun Rivaroxaban))) in addition to antiplatelet agents. 6.previous history of thrombocytopenia or coagulation disorders. 7.previous history of atrial fibrillation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative major adverse cardiovascular cerebrovascular and peripheral vessel events;Postoperative intracranial bleeding ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative function outcome in 90 days;Postoperative total mortality in 90 days; | — |
Countries
China
Contacts
Public ContactShuo Wang
Beijing Tiantan Hospital, Capital Medical University
Outcome results
None listed